Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why in the world would IOVA do a 25 for 1 reverse split? They have enough cash on hand to last through the end of 2025. Someone is getting awfully desperate. Good news must be close. Just checked out yahoo finance. The shorts are out in full force.
Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration
GlobeNewswireJune 18, 2020
Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19
Results Expected to Support Tonix’s Anticipated Regulatory Filings for TNX-1800, a Live Replicating Virus Vaccine Designed to Elicit T Cell Immunity in Addition to Antibodies
NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today an expansion of its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’s TNX-1800, which is a live replicating virus vaccine designed to protect against COVID-19. The data will support the interpretation of animal trial results with TNX-1800, which are expected in the fourth quarter of 2020 and subsequent human trials.
“More than 200 years of vaccine experience, beginning with Dr. Edward Jenner’s landmark discoveries with horsepox and cowpox vaccines, have shown that T cell eliciting vaccines are particularly effective against viruses,” said Seth Lederman, M.D., President and CEO of Tonix. “We believe that protective vaccines against the SARS-CoV-2 virus will be similar in that regard. The data we plan to collect from recovered and asymptomatic COVID-19 volunteers will inform vaccine development on how to safely provide to vaccine recipients the same immune responses that others got from recovering from actual CoV-2 infection. If approved by the U.S. Food and Drug Administration (FDA) for use in healthy, non-pregnant adults without moderate or severe eczema, TNX-1800 would feature single-dose immunity without the use of adjuvants, ease of manufacturing on readily available systems, and glass-sparing distribution since we believe 100 doses of TNX-1800 could be packaged in a single vial. Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed.”
Dr. Lederman, a former tenured professor at Columbia Medical School, who has made original contributions to immunology and virology, continued, “Tonix’s TNX-1800 is based on a virus that we believe is closely related to Dr. Jenner’s first vaccine. Vaccines that descended from Dr. Jenner’s vaccine were used to eradicate smallpox globally, the only virus ever successfully eradicated. Smallpox was spread through the respiratory route, but it was eradicated with a vaccine administered in the arm. Tonix’s lead COVID-19 vaccine candidate, TNX-1800, is designed to elicit a predominant T cell response, with some antibody response, while three other early candidates in the Company’s vaccine portfolio are designed to elicit almost pure T cell responses.” Dr. Lederman added, “The features of a protective immune response to SARS-CoV-2 remain unknown. But since SARS-CoV-2 is a virus, we believe that T cell responses, in particular T Helper Type 1, or TH1 responses, will play an important if not dominant role in protecting against serious illness from COVID-19. These studies will provide us with a blueprint for interpreting the results of planned animal and human studies with TNX-1800.”
Raj Kalkeri, Ph.D., from Southern Research and technical lead for this study, said, “This is groundbreaking research with regards to COVID-19. As scientists, we know that the most successful vaccines mimic and potentiate how the immune system responds to an invader. This additional work we are doing with Tonix will add focus to that objective. We are looking forward to a timely completion of this study, utilizing readouts from a variety of assays that can provide information about TH1 or other types of immunity.”
An expert team of scientists from Southern Research, including Raj Kalkeri, Ph.D., Elizabeth Wonderlich, Ph.D., John Farmer, Ph.D. and Fusataka Koide, Director of Virology, is working on this collaboration.
About TNX-1800, TNX-1810, TNX-1820, TNX-1830 and TNX-801*
TNX-1800 is a live modified horsepox virus vaccine for percutaneous administration that is designed to express the Spike protein of the SARS-CoV-2 virus that causes COVID-19 and to elicit a predominant T cell response. TNX-1810, TNX-1820 and TNX-1830 are modified horsepox viruses that are designed to express different SARS-CoV-2 proteins than Spike and to elicit almost pure T cell responses. TNX-801 is a live horsepox virus vaccine 1. Horsepox and vaccinia are closely related orthopoxviruses that are believed to share a common ancestor. Live replicating orthopoxviruses, like vaccinia or horsepox, can be engineered to express foreign genes and have been explored as platforms for vaccine development because they possess; (1) large packaging capacity for exogenous DNA inserts, (2) precise virus-specific control of exogenous gene insert expression, (3) lack of persistence or genomic integration in the host, (4) strong immunogenicity as a vaccine, (5) ability to rapidly generate vector/insert constructs, (6) readily manufacturable at scale, and (7) ability to provide direct antigen presentation. Relative to vaccinia, horsepox has substantially decreased virulence in mice1. TNX-801 vaccinated macaques showed no overt clinical signs after monkeypox challenge2. Horsepox-based vaccines are designed to be single dose, vial-sparing vaccines, which can be manufactured on conventional cell culturing systems, with the potential for mass scale production.
Hey Bigboard,
Can you please come with something original or at least different, good grief man you post the same thing on every board you post on. No secret to your posting agenda.
You're very boring!
Nice DD Stephen
Thanks for sharing!
Here is some good news from an article posted yesterday!!! https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
Oh look, I see Tonix Pharmaceuticals on the list. Dr. Fauci is now saying the virus could be seasonal.
Big Board you gotta be happy and to think of all the lives their vaccine could save. If their vaccine is approved, it's a win win for TNXP shareholders and people around the world.
JMHO!
Any Whales here? We need some big boys here to burn the shorts.
I hope so.
Good Point Joe!
We need a catalyst to move this thing upward.
Smart Money,
Curious to hear your thoughts on Institutions agenda. No doubt someone holding this one down for the past 6 months or so. They won't let it go above .80/share.
Surely they don't won't to keep this below $1.00?
Is the public offering still on the table, if so when will that take place.
Like to hear your thoughts on a reverse split.
Thanks Bridgeman. Did that update apply to PRPM as well or just TDEY and Suti?
One of the 3 Amigos posted a few weeks ago that Eddie V. was trying to sell PRPM.
Thanks for dropping by StockPro
StockPro72
Sure could use you on the PRPM message board. Someone needs to kick start that too.
Item 1.02. Termination of a Material Definitive Agreement.
As previously reported, on February 1, 2013, Capricor, Inc. (“Capricor”), a wholly owned subsidiary of Capricor Therapeutics, Inc. (the “Company”), and the California Institute for Regenerative Medicine (“CIRM”) entered into a Notice of Loan Award and Loan Agreement (collectively the “Loan Award”). In 2015, the Company entered into a Joinder Agreement with Capricor and CIRM, pursuant to which, among other things, the Company agreed to become a loan party under the Loan Award. Pursuant to the Loan Award, CIRM loaned Capricor approximately $15.6 million, which includes accrued interest (the “Loan Balance”).
On December 11, 2017, Capricor and CIRM entered into Amendment No. 3 to the CIRM Notice of Loan Award (DR2A-05735) (“Amendment No. 3”) whereby the total Loan Balance under the Loan Award has been forgiven by CIRM thereby terminating Capricor and the Company’s obligation to repay the Loan Balance.
The decision to terminate the Loan Award and forgive the Loan Balance was due to the abandonment of the ALLSTAR project at the end of the project period in accordance with Section 4.10 of the Loan Agreement and Article VII, Section I of the CIRM Loan Administration Policy. In November 2017, Capricor completed the final operational milestone under the terms of the Loan Award. The foregoing description of Amendment No. 3 does not purport to be complete and is qualified in its entirety by reference to the full text of Amendment No. 3, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01. Other Events.
Pro Forma Balance Sheet
In connection with Amendment No. 3 to the Loan Award described in Item 1.02, an unaudited condensed consolidated pro forma balance sheet of the Company as of September 30, 2017 is attached as Exhibit 99.1 to this Current Report on Form 8-K. The unaudited condensed consolidated pro forma balance sheet has been prepared to reflect the forgiveness of the Loan Balance under the Loan Award, which occurred subsequent to the fiscal quarter ended September 30, 2017, as if the events occurred on September 30, 2017. The unaudited condensed consolidated pro forma balance sheet does not reflect any other subsequent events. The attached unaudited condensed consolidated pro forma balance sheet does not necessarily reflect the financial position or results of operations that would have actually resulted had the loan forgiveness occurred as of the dates indicated, nor should it be taken as necessarily indicative of the future financial position or results of operations of the Company.
The unaudited condensed consolidated pro forma financial information is provided for information purposes only, and should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the SEC on November 14, 2017 (the “Form 10-Q”), and the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 16, 2017 (the “Form 10-K”), including the more detailed financial statements and notes thereto included therein.
The pro forma financial information is subject to risks and uncertainties, including those discussed in the Form 10-Q and the Form 10-K under the caption “Risk Factors”.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
10.1 Amendment No. 3 to the CIRM Notice of Loan Award, dated December 11, 2017
99.1 Pro Forma Balance Sheet of Capricor Therapeutics, Inc. as of September 30, 2017.
SIGNATURES
$15.5 no of debt just been forgiven by CIRM. it makes them almost debt free
This posted on another message board.
Share price up over 35% in pre-market trading this morning. Time for ClayTrader and his chicken charts.
Wondering the same thing. Thought we might see a nice pop after the presentation.
Guess we can thank Clay Trader and his cronies for walking this down. A few weeks ago they walked it back down near $2.00!
Very good trial results. Conference Call @ 4:30 p.m. today for those that want to listen. Only posted 1st part of press release.
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy
•November 15, 2017
Comment
Dr. Ronald G. Victor Presents 12-Month Results of HOPE Clinical Trial at AHA Late-Breaking Session
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET
ANAHEIM, Calif., Nov. 15, 2017 /PRNewswire/ -- Boys and young men in advanced stages of Duchenne muscular dystrophy experienced significant and sustained improvements in cardiac structure and function, as well as skeletal muscle function, following treatment with CAP-1002, the lead investigational therapy under development at Capricor Therapeutics (CAPR). These findings were reported today by Ronald G. Victor, M.D. at a Late-Breaking Science session of the American Heart Association Scientific Sessions 2017.
Thanks UFO,
I thought it was illegal.
# 1, how reliable is your source?
Hey Pres46,
I don't have PM so I will respond to your message Friday if I'm near a computer.
Have to admit you were right about the outcome of FPFI and Kevin Quirk. Wish I listened to you about a year ago and maybe I wouldn't be a bagholder!
Sadly, I purchased some shares for my daughter as well.
Thanks for being honest. Unfortunately I assume lot of folks posting on these boards have an agenda.
Have a good day.
I think someone posted about this several months back and mentioned Martha Stewart's case. Wasn't she convicted of a felon and is still CEO of MSO or whatever the name of her company is.
Hey Pres46,
Wondering when you were going to chime in?
Good Luck there goarmy123.
No way I would ever again take a chance on any of Roxanne's companies. I've already lost enough money trading her stocks. Still a bagholder on EMXC and MPIX. I've got enough bags to last me a life time!
Wouldn't touch this with a 10 ft. pole.
JMHO
Jobur,
Unfortunately no one will ever recover their money from her other companies (EMXC and MPIX). She was actually forced out of MPIX. Then Victor S. ran it into the ground. If you recover 50% of your investment in HWAL you will be one of the lucky ones.
Lots of people lost lots of money believing her lies and unfulfilled promises. She was working with Eddie Vasker at one time on a women's football league and some other projects. Of course nothing ever came to fruition.
Check out PRPM, SUTI and TDEY and you can see Eddie uses the same business plan as Roaxanne Weber or Green. She knows how to play people.
Odd how some people want everybody else to do their DD for them!
Based on what?
Dude,
Check the message boards on EMXC and HWAL. Roxanne Weber was the CEO of MPIX and EMXC at one time. She was kicked out and good old Victor S. took over using the same business plan, Sale shares. Now she's running HWAL with the music library that belongs to EMXC. She was doing some collaborations with Eddie Vasker a few years back, another crook in pinky land. Check out PRPM, TDEY and SUTI to name a few of his money making shells.
Do your homework. I'm still a bag holder in both EMXC and MPIX. I like most shareholders hoped someone could turn EMXC and MPIX into a viable company.
Wolf made out like a fat cat but, shareholders were left holding the bag.
Be careful here folks. This is another Wolf Pack play. He alerted it this morning at the open.
Thanks for the update. Guess I was wrong about Kevin Q. and FPFI.
Received this e-mail today. Who the hell is driving the ship?
?
Harvest Soul <info@harvestsoul.com>
To
Today at 1:02 PM
Announcing Harvest Soul Probiotic Juice
Now Available Online!
We are thrilled to announces the release of a Probiotic line of organic, high fiber juices enhanced with GanedenBC30®. The latest addition to Harvest Soul’s growing lineup of Chewable and Blended juice products, the Probiotic line includes PRO Tropical, PRO Greens, PRO Beet and PRO Berry varieties.
Available online now and at various retail locations throughout the Southeast beginning this Spring, the Probiotic Juice retails for $5.99 per 12 ounce bottle and contains up to 2 billion CFUs of GanedenBC30®, a highly effective and proven probiotic that keeps good and bad bacteria in proper balance for a healthy digestive function and immune system. The USDA organic, non-GMO Probiotic Juices combine powerful probiotics with healthy juices from nutritious leafy greens and anti-oxidant rich fruits and veggies.
We are committed to providing delicious juices that retain the healthy fiber typically juiced away in traditional processes. Made from whole fruits and vegetables and never from concentrates, Harvest Soul juices do not add sweeteners and are also gluten free. All Harvest Soul juices are USDA Organic and Non-GMO Project verified, ensuring premium quality.
We will be showcasing our Probiotic Juices at the Natural Products Expo West trade show in Anaheim March 10-12 at booth H113.
We hope to see you there!
Right you are bro and I bet The Wolfe is howling all the way to da bank. Wolfe and his gang doing what Wolfe does.
NunyaBidness,
Thanks for sharing your experience. Glad to hear some facts rather than constant bashing as is usually the case.
Trust me, a lot of folks have been burnt by these over-the-counter CEO's that make a living by screwing good hard working shareholders. I had the same type experience with 4 different CEO's.
All I can say is they better enjoy their fun while they can because the good Lord won't let there evil deeds go unpunished. I suggest they read, "23 Minutes in Hell", written by Bill Weiss and they might want to change their ways.
I lost about $12,000 of my 401 K money with one company plus an additional $ 8,000 in he same company believing their promises, not to mention some of my daughters 401K money as well.
Odd that 95% of the problems that repeatedly get communicated on this board were all inherited by Kent from old management.
People that choose to live in the past always miss the future!
132 million buys to 27 million sells today.
OK Kent!
Get Er Done!!!!!!!!!!
Fry the shorts off the shorts.
Once symbol change approved, someone has to cover all those naked short shares of TDEY.
Ouch!!!!!!!!